UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms

European journal of clinical pharmacology, 2013-04, Vol.69 (4), p.937-948

2013

Volltextzugriff (PDF)

Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole

Clinical pharmacokinetics, 2016-12, Vol.55 (12), p.1535-1545

2016

Volltextzugriff (PDF)

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

British journal of clinical pharmacology, 2009-12, Vol.68 (6), p.906-915

2009

Volltextzugriff (PDF)

CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

Journal of clinical pharmacology, 2009-02, Vol.49 (2), p.196-204

2009

Volltextzugriff (PDF)

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

Clinical and translational science, 2021-03, Vol.14 (2), p.487-491

2021

Volltextzugriff (PDF)

Promising adoption of an electronic clinical decision support system for antenatal and intrapartum care in rural primary healthcare facilities in sub-Saharan Africa: The QUALMAT experience

International journal of medical informatics (Shannon, Ireland), 2015-09, Vol.84 (9), p.647-657

2015

Volltextzugriff (PDF)

Health workers' knowledge of and attitudes towards computer applications in rural African health facilities

Global health action, 2014-01, Vol.7 (1), p.24534-24534

2014

Volltextzugriff (PDF)

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring

Therapeutic drug monitoring, 2011-02, Vol.33 (1), p.86

2011

Volltextzugriff (PDF)

Development of an algorithm to detect and reduce complexity of drug treatment and its technical realisation

BMC medical informatics and decision making, 2020-07, Vol.20 (1), p.154-154, Article 154

2020

Volltextzugriff (PDF)

Clarithromycin substantially increases steady‐state bosentan exposure in healthy volunteers

British journal of clinical pharmacology, 2014-01, Vol.77 (1), p.141-148

2014

Volltextzugriff (PDF)

Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011

International journal of cardiology, 2011-12, Vol.154, p.S20-S33

2011

Volltextzugriff (PDF)

Midazolam microdose to determine systemic and pre‐systemic metabolic CYP3A activity in humans

British journal of clinical pharmacology, 2015-02, Vol.79 (2), p.278-285

2015

Volltextzugriff (PDF)

Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo

Circulation (New York, N.Y.), 1995-03, Vol.91 (5), p.1314-1319

1995

Volltextzugriff (PDF)

Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses

British journal of clinical pharmacology, 2019-10, Vol.85 (10), p.2310-2320

2019

Volltextzugriff (PDF)

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

Clinical pharmacokinetics, 2024-04, Vol.63 (4), p.469-481

2024

Volltextzugriff (PDF)

Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity

Journal of clinical pharmacology, 2021-06, Vol.61 (6), p.789-798

2021

Volltextzugriff (PDF)

Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug–Drug Interactions with Potential Perpetrator Drugs

Clinical pharmacokinetics, 2019-09, Vol.58 (9), p.1155-1163

2019

Volltextzugriff (PDF)

Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics

British journal of clinical pharmacology, 2017-09, Vol.83 (9), p.1954-1965

2017

Volltextzugriff (PDF)

Nesting doctoral students in collaborative North-South partnerships for health systems research

Global health action, 2014-01, Vol.7 (1), p.24070-24070

2014

Volltextzugriff (PDF)

Perpetrator effects of ciclosporin (P‐glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers

British journal of clinical pharmacology, 2019-07, Vol.85 (7), p.1528-1537

2019

Volltextzugriff (PDF)

A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19

Cytokine (Philadelphia, Pa.), 2021-02, Vol.138, p.155399-155399, Article 155399

2021

Volltextzugriff (PDF)

Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

British journal of clinical pharmacology, 2018-12, Vol.84 (12), p.2903-2913

2018

Volltextzugriff (PDF)

Factors influencing alert acceptance: a novel approach for predicting the success of clinical decision support

Journal of the American Medical Informatics Association : JAMIA, 2011-07, Vol.18 (4), p.479-484

2011

Volltextzugriff (PDF)

Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor

Analytical and bioanalytical chemistry, 2015-09, Vol.407 (22), p.6815-6825

2015

Volltextzugriff (PDF)

An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma

Journal of pharmaceutical and biomedical analysis, 2019-09, Vol.174, p.633-638

2019

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Aktive Filter

ThemaAged

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(65)

Sprache

Englisch
(65)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms

Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype

CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

Promising adoption of an electronic clinical decision support system for antenatal and intrapartum care in rural primary healthcare facilities in sub-Saharan Africa: The QUALMAT experience

Health workers' knowledge of and attitudes towards computer applications in rural African health facilities

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring

Development of an algorithm to detect and reduce complexity of drug treatment and its technical realisation

Clarithromycin substantially increases steady‐state bosentan exposure in healthy volunteers

Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011

Midazolam microdose to determine systemic and pre‐systemic metabolic CYP3A activity in humans

Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo

Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity

Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug–Drug Interactions with Potential Perpetrator Drugs

Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics

Nesting doctoral students in collaborative North-South partnerships for health systems research

Perpetrator effects of ciclosporin (P‐glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers

A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19

Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

Factors influencing alert acceptance: a novel approach for predicting the success of clinical decision support

Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor

An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma

Aktive Filter

Suchergebnisse filtern